iShares NASDAQ US Biotechnology UCITS ETF (ETR:2B70)
Germany
· Delayed Price · Currency is EUR | Assets | 411.18M |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -5.75% |
| Volume | 24,202 |
| Open | 5.37 |
| Previous Close | 5.32 |
| Day's Range | 5.27 - 5.37 |
| 52-Week Low | 4.70 |
| 52-Week High | 6.74 |
| Beta | 0.78 |
| Holdings | 273 |
| Inception Date | Oct 19, 2017 |
About 2B70
iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sector. The fund invests in the stocks of companies across all market capitalizations. It seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing representative sampling methodology. iShares NASDAQ US Biotechnology UCITS ETF was formed on October 19, 2017 and is domiciled in Ireland.
Performance
2B70 had a total return of -5.75% in the past year, including dividends. Since the fund's inception, the average annual return has been 0.80%.
Top 10 Holdings
48.53% of assets| Name | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8.97% |
| Gilead Sciences, Inc. | GILD | 8.12% |
| Amgen Inc. | AMGN | 7.94% |
| Regeneron Pharmaceuticals, Inc. | REGN | 7.03% |
| AstraZeneca PLC | AZN | 4.42% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 3.42% |
| Summit Therapeutics Inc. | SMMT | 2.95% |
| argenx SE | ARGX | 2.10% |
| Biogen Inc. | BIIB | 1.91% |
| Sanofi | SNY | 1.68% |